High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily

about

High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily

Item

http://www.wikidata.org/entity/Q56910903

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 01 November 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

High prevalence and long durat ...... taking efavirenz 600 mg daily

@en

High prevalence and long durat ...... taking efavirenz 600 mg daily

@nl

type

Item

label

High prevalence and long durat ...... taking efavirenz 600 mg daily

@en

High prevalence and long durat ...... taking efavirenz 600 mg daily

@nl

prefLabel

High prevalence and long durat ...... taking efavirenz 600 mg daily

@en

High prevalence and long durat ...... taking efavirenz 600 mg daily

@nl

P1476

High prevalence and long durat ...... taking efavirenz 600 mg daily

@en

P2093

Daniel Kiiza

http://www.w3.org/2001/XMLSchema#string

Eva Laker

http://www.w3.org/2001/XMLSchema#string

Mohammed Lamorde

http://www.w3.org/2001/XMLSchema#string

Walter J Arinaitwe

http://www.w3.org/2001/XMLSchema#string

P2860

Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients

Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection

Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool

Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)

Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study

Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.

Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials.

A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.

Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.

P304

3158-3161

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKY298

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Catriona John Waitt

Kay Seden

S Khoo

P577

2018-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30085168

http://www.w3.org/2001/XMLSchema#string

P921

Uganda

Farmakologi

infectious disease

P932

6198741

http://www.w3.org/2001/XMLSchema#string